Healthy Skepticism Library item: 8422
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Sibbald B.
Quebec allows Vioxx class-action suit.
CMAJ 2007 Jan 2; 176:(1):20
http://www.cmaj.ca/cgi/content/full/176/1/20
Keywords:
Publication Types:
News
MeSH Terms:
Cyclooxygenase 2 Inhibitors/adverse effects*
Drug Industry/legislation & jurisprudence*
Humans
Lactones/adverse effects*
Myocardial Infarction/chemically induced
Quebec
Sulfones/adverse effects*
Substances:
Cyclooxygenase 2 Inhibitors
Lactones
Sulfones
rofecoxib
Full text:
The Quebec Superior Court has set a worldwide precedent in granting plaintiffs class-action status in a suit against Merck Frosst Canada Ltd., the Canadian manufacturer of rofecoxib (Vioxx).
US parent Merck & Co. Inc., announced Sept. 30, 2004, a voluntary worldwide withdrawal of rofecoxib (Vioxx) after a study showed patients taking the anti-inflammatory drug on a long-term basis face twice the risk of a heart attack compared with patients receiving placebo (CMAJ 2004;171:1027-8).
The Nov. 9 Quebec court decision marks the first personal injury class-action suit authorized in the swirl of litigation surrounding rofecoxib. The Canadian class action was filed by 2 plaintiffs, who allege that they suffered heart attacks after using rofecoxib for more than 3 years. About 4000 Quebeckers who used the drug between 1999 and 2004 may be represented in the suit.
Merck may seek a motion to de-authorize the class action on the grounds that each plaintiff’s case is unique.
In the US, Merck is arguing each case separately and faces more than 42 000 lawsuits. So far, Merck has won 5 Vioxx cases and lost 4. A class-action suit on behalf of unions, health plans and over third-party payers who covered rofecoxib prescriptions has been authorized in the state of New Jersey.
Rofecoxib, a selective COX-2 inhibitor, nonsteroidal anti-inflammatory drug (NSAID) gained Canadian approval in 1999 for the treatment of acute and chronic symptoms of osteoarthritis, rheumatoid arthritis, acute pain and menstrual pain. IMS Health Canada reports that rofecoxib was the number 10 top-selling drug in Canada in 2003, with 3.3 million prescriptions written and retail sales totaling $194 million.
Merck is expecting a decision from the US Food and Drug Administration by April on its application for approval of Arcoxia, its COX-2 inhibitor for people suffering from osteoarthritis. – Barbara Sibbald, CMAJ
